By TIME Video
The Food and Drug Administration approved on Wednesday a new pain pill that was created to discourage abuse, the Associated Press reports.
The new pill, Targiniq ER, combines oxycodone, a potentially addictive opioid used in many pain medications, with naloxone, often used to trim the effects of opioids. The naloxone isn’t activated if the pill is swallowed as normal. If a would-be drug abuser crushes the pill to snort or inject it, however, the naloxone activates. That can potentially make Targiniq ER less attractive to abusers.
“Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection,” FDA said in a statement.
More Must-Reads from TIME
- The 100 Most Influential People in AI 2024
- Inside the Rise of Bitcoin-Powered Pools and Bathhouses
- How Nayib Bukele’s ‘Iron Fist’ Has Transformed El Salvador
- What Makes a Friendship Last Forever?
- Long COVID Looks Different in Kids
- Your Questions About Early Voting , Answered
- Column: Your Cynicism Isn’t Helping Anybody
- The 32 Most Anticipated Books of Fall 2024
Contact us at letters@time.com